New subgroup analyses of CLEAR Outcomes data showed bempedoic acid reduced the risk of major adverse cardiovascular events across various patient groups
First-in-class cholesterol-lowering treatment NILEMDO®? and its combination with ezetimibe, NUSTENDI®?, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk
Enforcement Report - Week of April 24, 2024
CHMP positive opinions for bempedoic acid and the bempedoic acid / ezetimibe
FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET®
Enforcement Report - Week of September 13, 2023
MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced results from two prespecified analyses from the Phase 3 CLEAR (Cholesterol Lowering via Bempedoic Acid, an ATP citrate lyase (ACL)-Inhibiting Regimen) Outcomes trial. The results, presented at the European Society of Cardiology (ESC) Congress 2023, further support the long-term use of bempedoic acid in patients at high-risk of cardiovascular (CV) events and demonstrate particular benefit in those with diabetes.
MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced the presentation of results from the Phase 3 cardiovascular CLEAR (Cholesterol Lowering via Bempedoic acid, an ATP citrate lyase (ACL)-Inhibiting Regimen) Outcomes Trial and the multinational observational SANTORINI (Lipid management in patients with high- and very-high CV risk; data from clinical practice in Europe) study. Both studies were presented in a late-breaker session at the 91st European Atherosclerosis Society congress.